AR115016A1 - Moduladores de receptores acoplados a la proteína g - Google Patents
Moduladores de receptores acoplados a la proteína gInfo
- Publication number
- AR115016A1 AR115016A1 ARP190100749A ARP190100749A AR115016A1 AR 115016 A1 AR115016 A1 AR 115016A1 AR P190100749 A ARP190100749 A AR P190100749A AR P190100749 A ARP190100749 A AR P190100749A AR 115016 A1 AR115016 A1 AR 115016A1
- Authority
- AR
- Argentina
- Prior art keywords
- chemical entities
- glp
- gipr
- disorder
- disease
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102100039997 Gastric inhibitory polypeptide receptor Human genes 0.000 abstract 4
- 150000005829 chemical entities Chemical class 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 101000886866 Homo sapiens Gastric inhibitory polypeptide receptor Proteins 0.000 abstract 3
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 2
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 abstract 2
- 230000008484 agonism Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000011664 signaling Effects 0.000 abstract 2
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 abstract 1
- 102000051325 Glucagon Human genes 0.000 abstract 1
- 108060003199 Glucagon Proteins 0.000 abstract 1
- 101710176384 Peptide 1 Proteins 0.000 abstract 1
- 230000008485 antagonism Effects 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 abstract 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente se refiere a entidades químicas (por ejemplo, un compuesto o una sal y/o hidrato y/o profármaco del compuesto farmacéuticamente aceptable) que modulan (por ejemplo, agonizan o agonizan parcialmente o antagonizan a) el receptor del péptido-1 similar al glucagón (GLP-1R) y/o el receptor del polipéptido inhibidor gástrico (GIPR). Las entidades químicas son útiles, por ejemplo, para tratar un sujeto (por ejemplo, un humano) que tiene una enfermedad, trastorno, o condición en el cual la modulación (por ejemplo, agonismo, agonismo parcial o antagonismo) de las actividades del GLP-1R y/o GIPR es benéfica para el tratamiento o prevención de la patología subyacente y/o síntomas y/o progreso de la enfermedad, trastorno, o condición. En algunas modalidades, la modulación resulta en un mejoramiento de (por ejemplo, un incremento en) niveles existentes (por ejemplo, niveles normales o por debajo de los normales) de la actividad de GLP-1R y/o GIPR (por ejemplo, señalización). En algunas modalidades, las entidades químicas descritas en la presente modulan además (por ejemplo, atenúan, desacoplan) la señalización de b-arrestina con relación a aquella que se observa con el ligando nativo. Esta descripción también caracteriza composiciones así como también otros métodos para usar y elaborar tales entidades químicas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862647604P | 2018-03-23 | 2018-03-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR115016A1 true AR115016A1 (es) | 2020-11-18 |
Family
ID=67986596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190100749A AR115016A1 (es) | 2018-03-23 | 2019-03-25 | Moduladores de receptores acoplados a la proteína g |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11535660B1 (es) |
| EP (1) | EP3768294A4 (es) |
| JP (1) | JP2021531259A (es) |
| KR (1) | KR20210008834A (es) |
| CN (1) | CN112236161A (es) |
| AR (1) | AR115016A1 (es) |
| AU (1) | AU2019237507A1 (es) |
| BR (1) | BR112020019148A2 (es) |
| CA (1) | CA3094820A1 (es) |
| EA (1) | EA202092269A1 (es) |
| IL (2) | IL311177A (es) |
| MX (1) | MX2020009950A (es) |
| PH (1) | PH12020551539A1 (es) |
| SG (1) | SG11202009338SA (es) |
| WO (1) | WO2019183577A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022272251A1 (en) * | 2021-05-13 | 2023-11-16 | Carmot Therapeutics Inc. | Modulators of g-protein coupled receptors |
| KR20230062994A (ko) | 2021-11-01 | 2023-05-09 | 국민대학교산학협력단 | 글루카곤 유사 펩타이드-1 수용체의 양성 알로스테릭 조절제의 스크리닝 방법 및 그 방법에 따라 스크리닝된 글루카곤 유사 펩타이드-1 수용체의 양성 알로스테릭 조절제 |
| WO2024033374A1 (en) | 2022-08-11 | 2024-02-15 | Syngenta Crop Protection Ag | Novel arylcarboxamide or arylthioamide compounds |
| WO2024089216A1 (en) | 2022-10-27 | 2024-05-02 | Syngenta Crop Protection Ag | Novel sulfur-containing heteroaryl carboxamide compounds |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997010224A1 (en) | 1995-09-13 | 1997-03-20 | Takeda Chemical Industries, Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
| US6432947B1 (en) | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
| JP2002506792A (ja) * | 1998-02-27 | 2002-03-05 | ノボ ノルディスク アクティーゼルスカブ | Ｎ末端修飾ｇｌｐ−１誘導体 |
| PL202367B1 (pl) * | 1998-12-07 | 2009-06-30 | Sod Conseils Rech Applic | Związki stanowiące analogi GLP-1, kompozycje zawierające te związki oraz zastosowanie tych związków |
| WO2001062765A2 (en) | 1999-02-26 | 2001-08-30 | Arena Pharmaceuticals, Inc. | Small molecule modulators of g protein-coupled receptor six |
| JP2003508501A (ja) | 1999-09-07 | 2003-03-04 | コンジュケム，インコーポレーテッド | 生物学的結合のための肺送達 |
| US20030187023A1 (en) | 2000-07-17 | 2003-10-02 | Keiji Kubo | Sulfone derivatives, process for their production and use thereof |
| BR0315815A (pt) | 2002-11-01 | 2005-09-13 | Takeda Pharmaceutical | Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto |
| EP2385032A1 (en) | 2002-11-08 | 2011-11-09 | Takeda Pharmaceutical Company Limited | GPR40 Receptor function regulator |
| EP1564213A4 (en) | 2002-11-22 | 2009-05-27 | Takeda Pharmaceutical | IMIDAZOLE DERIVATIVES, PROCESS FOR THE PRODUCTION AND USE THEREOF |
| US20050059605A1 (en) | 2003-01-31 | 2005-03-17 | Krishna Peri | Chemically modified metabolites of regulatory peptides and methods of producing and using same |
| EP1630152A4 (en) | 2003-05-30 | 2009-09-23 | Takeda Pharmaceutical | CONNECTION WITH CONDENSED RING |
| EP2932981B1 (en) * | 2003-09-19 | 2021-06-16 | Novo Nordisk A/S | Albumin-binding derivatives of GLP-1 |
| WO2005030740A1 (ja) | 2003-09-30 | 2005-04-07 | Takeda Pharmaceutical Company Limited | チアゾリン誘導体およびその用途 |
| EP1695961A4 (en) | 2003-12-17 | 2007-10-24 | Takeda Pharmaceutical | UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE |
| TW200523247A (en) | 2003-12-25 | 2005-07-16 | Takeda Pharmaceutical | 3-(4-benzyloxyphenyl) propanoic acid derivatives |
| WO2005063725A1 (ja) | 2003-12-26 | 2005-07-14 | Takeda Pharmaceutical Company Limited | フェニルプロパン酸誘導体 |
| US7786165B2 (en) | 2004-03-15 | 2010-08-31 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
| EP2253315A1 (en) | 2004-03-30 | 2010-11-24 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
| TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
| US20060275288A1 (en) | 2005-01-20 | 2006-12-07 | Grihalde Nelson D | GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof |
| JP5094394B2 (ja) | 2005-04-20 | 2012-12-12 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| JP2008539735A (ja) * | 2005-05-06 | 2008-11-20 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | グルカゴン様ペプチド１（ｇｌｐ−１）受容体アンタゴニストおよびそれらの薬理学的使用方法 |
| EP1911738A4 (en) | 2005-07-29 | 2009-12-16 | Takeda Pharmaceutical | PHENOXYALKANSÄUREVERBINDUNG |
| JP5084503B2 (ja) | 2005-07-29 | 2012-11-28 | 武田薬品工業株式会社 | シクロプロパンカルボン酸化合物 |
| MX2008001386A (es) | 2005-08-10 | 2008-04-07 | Takeda Pharmaceutical | Agente terapeutico para diabetes. |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| CN101420941A (zh) * | 2006-04-11 | 2009-04-29 | 艾尼纳制药公司 | Gpr119受体激动剂用于增加骨质量和用于治疗骨质疏松症的用途,和其相关组合疗法 |
| ME00535B (me) | 2006-06-27 | 2011-10-10 | Takeda Pharmaceuticals Co | Fuzionisana ciklična jedinjenja |
| WO2008021560A2 (en) * | 2006-08-17 | 2008-02-21 | Amylin Pharmaceuticals, Inc. | Dpp-iv resistant gip hybrid polypeptides with selectable properties |
| EP2298772A1 (en) | 2006-10-18 | 2011-03-23 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| US8410087B2 (en) | 2006-10-19 | 2013-04-02 | Takeda Pharmaceutical Company Limited | Indole compound |
| EP2128138A1 (en) | 2007-01-29 | 2009-12-02 | Takeda Pharmaceutical Company Limited | Pyrazole compound |
| WO2008099794A1 (en) | 2007-02-09 | 2008-08-21 | Takeda Pharmaceutical Company Limited | Fused ring compounds as partial agonists of ppar-gamma |
| WO2008136428A1 (ja) | 2007-04-27 | 2008-11-13 | Takeda Pharmaceutical Company Limited | 含窒素５員複素環化合物 |
| WO2008156757A1 (en) | 2007-06-19 | 2008-12-24 | Takeda Pharmaceutical Company Limited | Indazole compounds for activating glucokinase |
| EA020326B9 (ru) * | 2008-06-17 | 2015-03-31 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения |
| TW201006821A (en) * | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
| US20120148586A1 (en) | 2009-08-27 | 2012-06-14 | Joyce Ching Tsu Chou | Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders |
| US8426414B2 (en) | 2009-10-09 | 2013-04-23 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
| KR20120123443A (ko) * | 2010-01-27 | 2012-11-08 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트 |
| US20120021979A1 (en) | 2010-06-24 | 2012-01-26 | Vanderbilt University | GLP-1 receptor modulation of addiction, neuropsychiatric disorders and erectile dysfunction |
| WO2013148579A1 (en) | 2012-03-29 | 2013-10-03 | Cebix Inc. | Pegylated c-peptide |
| CA2890190A1 (en) * | 2012-11-12 | 2014-05-15 | Redwood Bioscience, Inc. | Compounds and methods for producing a conjugate |
| ES2748162T3 (es) * | 2012-12-06 | 2020-03-13 | Victoria Link Ltd | Compuestos conjugados |
| US9766239B2 (en) | 2013-03-13 | 2017-09-19 | Arizona Board Of Regents On Behalf Of Arizona State University | Synbodies for detection of human norovirus |
| JP6659535B2 (ja) * | 2013-06-28 | 2020-03-04 | オークランド ユニサービシーズ リミティド | アミノ酸及びペプチド接合体及び接合方法 |
| US10011649B2 (en) | 2013-08-26 | 2018-07-03 | Arizona Board Of Regents On Behalf Of Arizona State University | High affinity synbodies for influenza |
| CA2967077A1 (en) * | 2014-11-14 | 2016-05-19 | Angiochem Inc. | Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin |
| WO2016131893A1 (en) | 2015-02-18 | 2016-08-25 | Medimmune Limited | Incretin fusion polypeptides |
| CN105219802A (zh) * | 2015-10-10 | 2016-01-06 | 广西大学 | 胰岛组织特异性表达GIPRdn慢病毒载体及其应用 |
| GB2551945B (en) * | 2015-12-18 | 2021-09-08 | Heptares Therapeutics Ltd | Novel GLP-1 receptor agonist peptides |
-
2019
- 2019-03-22 KR KR1020207030531A patent/KR20210008834A/ko unknown
- 2019-03-22 MX MX2020009950A patent/MX2020009950A/es unknown
- 2019-03-22 CN CN201980032743.8A patent/CN112236161A/zh active Pending
- 2019-03-22 IL IL311177A patent/IL311177A/en unknown
- 2019-03-22 WO PCT/US2019/023726 patent/WO2019183577A1/en unknown
- 2019-03-22 US US17/040,653 patent/US11535660B1/en active Active
- 2019-03-22 IL IL277495A patent/IL277495B1/en unknown
- 2019-03-22 CA CA3094820A patent/CA3094820A1/en active Pending
- 2019-03-22 JP JP2021500508A patent/JP2021531259A/ja active Pending
- 2019-03-22 SG SG11202009338SA patent/SG11202009338SA/en unknown
- 2019-03-22 EP EP19772275.4A patent/EP3768294A4/en active Pending
- 2019-03-22 BR BR112020019148-5A patent/BR112020019148A2/pt unknown
- 2019-03-22 AU AU2019237507A patent/AU2019237507A1/en active Pending
- 2019-03-22 EA EA202092269A patent/EA202092269A1/ru unknown
- 2019-03-25 AR ARP190100749A patent/AR115016A1/es unknown
-
2020
- 2020-09-23 PH PH12020551539A patent/PH12020551539A1/en unknown
-
2022
- 2022-12-22 US US18/087,063 patent/US20230357347A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230357347A1 (en) | 2023-11-09 |
| CA3094820A1 (en) | 2019-09-26 |
| EP3768294A1 (en) | 2021-01-27 |
| IL277495A (en) | 2020-11-30 |
| PH12020551539A1 (en) | 2021-06-07 |
| WO2019183577A1 (en) | 2019-09-26 |
| JP2021531259A (ja) | 2021-11-18 |
| IL311177A (en) | 2024-04-01 |
| EA202092269A1 (ru) | 2020-12-14 |
| CN112236161A (zh) | 2021-01-15 |
| BR112020019148A2 (pt) | 2021-01-26 |
| IL277495B1 (en) | 2024-04-01 |
| SG11202009338SA (en) | 2020-10-29 |
| MX2020009950A (es) | 2021-04-28 |
| EP3768294A4 (en) | 2022-05-04 |
| US11535660B1 (en) | 2022-12-27 |
| AU2019237507A1 (en) | 2020-10-08 |
| TW202012432A (zh) | 2020-04-01 |
| KR20210008834A (ko) | 2021-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR115016A1 (es) | Moduladores de receptores acoplados a la proteína g | |
| CO2019008932A2 (es) | Imidazo-quinolinas sustituidas como moduladores de nlrp3 | |
| PE20212198A1 (es) | Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1) | |
| BR112018071347A2 (pt) | moduladores de nlrp3 | |
| CL2019002314A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr). | |
| EA201991345A1 (ru) | Новые соединения в качестве пептидных тройных агонистов рецепторов glp1/глюкагона/gip | |
| CO2019005924A2 (es) | Agonistas duales acilados de glp-1/glp-2 | |
| CL2019002108A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr). | |
| EA201991600A1 (ru) | СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АРИЛУГЛЕВОДОРОДНЫЙ РЕЦЕПТОР (AhR) | |
| EA202190377A9 (ru) | Композиции ингибиторов cxcr4 и способы получения и применения | |
| AR099019A1 (es) | Módulos lanzadera monovalentes de la barrera hematocefálica | |
| EA201690660A1 (ru) | Соединения и способы на основе двойного агониста гип и гпп-1 | |
| AR080026A1 (es) | Metodos de tratamiento de enfermedades autoinmunitarias con antagonistas del ligando 4 similar a delta (dll4) | |
| PE20081546A1 (es) | Antagonistas del dr6 | |
| BR112019011461A2 (pt) | terapia celular à base de nk melhorada | |
| ECSP23093673A (es) | Moduladores de los receptores acoplados a proteínas g | |
| MX2021008081A (es) | Tratamiento de la enfermedad de sjogren con proteinas de fusion de nucleasa. | |
| CL2019003325A1 (es) | Uso novedoso de un agonista del receptor 2 de formil péptido / receptor a4de lipoxina (fpr2 / alx) para el tratamiento de la insuficiencia cardíaca. | |
| BR112016009962A2 (pt) | superagonistas de ação prolongada de hormônio glicoproteico | |
| BR112023025340A2 (pt) | Compostos de triptamina fluorada, análogos dos mesmos e métodos usando os mesmos | |
| CL2020000631A1 (es) | Uso de anticuerpos de unión a il-1b para el tratamiento de la hepatitis alcohólica. | |
| TH171839B (th) | แอนติบอดีที่มุ่งต้าน cd127 | |
| AR101856A1 (es) | Tratamiento de la fibrodisplasia osificante progresiva |